Survodutide Dual Agonist Obesity & MASH Research

What is Survodutide?

Survodutide is an investigational peptide-based dual agonist that activates the GLP-1 receptor and the glucagon receptor. The compound, also known as BI 456906, is co-developed by Boehringer Ingelheim and Zealand Pharma for obesity and MASH clinical research programmes.

The phrase “survodutide peptide” usually refers to this investigational GLP-1/glucagon dual agonist, not to a marketed Remy Peptides catalogue product. The dual mechanism is significant because glucagon signaling contributes to energy expenditure and hepatic lipid metabolism—the biological rationale underpinning survodutide’s development in both obesity and liver disease. For a head-to-head comparison with the leading triple agonist, see our survodutide vs retatrutide analysis. Another notable dual-agonist in clinical development is mazdutide (IBI362), which targets the same GLP-1/glucagon receptor pathways.

Survodutide Mechanism of Action: Glucagon and GLP-1 Receptors

Survodutide’s mechanism centres on simultaneous activation of the glucagon like peptide 1 (GLP-1) receptor and the glucagon receptor, giving it a GCGR/GLP-1R dual-agonist profile. The GLP-1 receptor is linked to appetite, insulin secretion, and gastric-emptying pathways in clinical research, while the glucagon receptor arm is studied for hepatic lipid oxidation and energy-expenditure effects.

Glucagon Like Peptide 1 and Energy Balance

Glucagon like peptide 1 is an incretin hormone released from intestinal L-cells in response to nutrient intake. Pure GLP-1 receptor agonist drugs use this pathway exclusively, whereas survodutide combines GLP-1 and glucagon receptor activation. The dual engagement is being studied to determine whether glucagon signaling adds measurable metabolic and hepatic effects beyond GLP-1 receptor agonism alone.

Subcutaneous Survodutide in Clinical Trials

Clinical trial protocols have evaluated once-weekly subcutaneous survodutide using sponsor-controlled dose-escalation designs. That wording describes trial methodology only and should not be read as administration guidance. The escalation schedules were designed to characterize exposure, tolerability, and gastrointestinal adverse-event patterns while maintaining consistent GLP-1 and glucagon receptor engagement in study settings.

Phase 2 Trial Design & Methodology

The pivotal Phase 2 obesity study for survodutide was a randomised, double blind, placebo controlled trial evaluating multiple dose levels in adults with overweight or obesity. The controlled trial enrolled participants with a body mass index (BMI) ≥30 kg/m² or ≥27 kg/m² with at least one weight-related comorbidity. Baseline characteristics included mean body weight of approximately 105 kg and mean body mass index of approximately 37 kg/m², consistent with other Phase 2 obesity trials in the incretin field.

Randomised and treated participants received sponsor-controlled subcutaneous study drug or placebo for up to 46 weeks. The double blind placebo controlled design ensured neither investigators nor participants knew treatment assignment, with interactive response technology used for randomisation and drug supply management. The clinical trial steering committee provided ongoing oversight of safety and protocol adherence throughout the study. Further drug evaluation and any eventual approval require completion of the broader clinical programme.

What Are Survodutide’s Obesity Trial Results?

SYNCHRONIZE-1 read out in May 2026 as the first Phase 3 obesity readout for survodutide — and the first dual-agonist Phase 3 readout outside Eli Lilly. In adults with obesity or overweight, survodutide produced 16.6% mean weight loss at 76 weeks, with absolute loss up to 17.8 kg (~39.2 lbs), versus 3.2% on placebo. The figure is a mean across all doses studied; dose-by-dose Phase 3 splits were not in the topline disclosure. Analyst commentary at readout noted survodutide fell short of tirzepatide’s SURMOUNT-1 (~22.5% at 72 wk) and retatrutide’s TRIUMPH-1 (28.3% at 80 wk) on pure weight loss, while leaving the glucagon arm open as a differentiator on cardiometabolic and liver outcomes.

Phase 2 remains useful reference data. Zealand’s pipeline materials report weight loss of up to 18.7% at 46 weeks at the 4.8 mg dose, with a clear dose-response across 0.6–4.8 mg. For the latest regulatory state, see our page on whether survodutide is approved yet. For broader incretin-candidate timing, see the 2026 obesity drug approval tracker.

Body Weight & BMI Outcomes by Dose

Survodutide produced dose-dependent bodyweight reductions across all active treatment groups in the Phase 2 trial. The dose response effects were clear: higher doses of survodutide resulted in greater body weight reduction, with the highest dose group achieving mean body weight loss of 18.7% at 46 weeks compared to approximately 2% in the placebo arm. Absolute body weight reductions exceeded 15 kg at the top dose level.

Greater bodyweight reduction is one efficacy marker in obesity and liver-disease drug development, but interpretation depends on trial design, baseline characteristics, and comparator arm. Mean body mass index decreased by approximately 7 points in the highest-dose group. Results from the Phase 2 trial were published in Diabetes, Obesity and Metabolism (Diabetes Obes Metab), supporting survodutide’s position as a closely watched dual agonist in clinical research.

Waist Circumference, Liver Fat and Body Composition Data

In the Phase 2 obesity trial, survodutide compared with placebo demonstrated significant reductions in waist circumference across all active dose groups. Investigators also tracked liver-fat and body-composition-related endpoints across the broader clinical programme. These are research endpoints, not individual outcome predictions, and should be interpreted through the population, comparator, and endpoint definitions used in each trial.

Percentage Change and Relative Change in Endpoints

Primary and secondary endpoints in the Phase 2 trial were reported as percentage change from baseline in body weight. The relative change in body weight at the top dose level—18.7% at 46 weeks—survodutide compared with placebo established the compound’s position in the competitive dual agonist landscape. Additional endpoints including relative change in waist circumference, fasting glucose, and HbA1c were also assessed in randomized and treated participants. Baseline characteristics of treated participants were balanced across treatment arms, supporting the validity of between-group comparisons. The relative change data were published with full access to supplementary materials.

Safety Profile & Adverse Events

The safety analysis of the Phase 2 trial showed that adverse events were predominantly gastrointestinal in nature, consistent with the GLP-1 receptor agonist class. The most commonly reported adverse events included nausea, diarrhoea, and vomiting, with incidence rates that increased with dose. Most GI adverse events were mild to moderate in severity and occurred primarily during the dose-escalation phase.

Serious adverse events were infrequent and balanced across treatment groups. Discontinuation rates due to adverse events were low overall but higher at the top dose level. The safety analysis did not reveal unexpected safety signals beyond the known GLP-1 class effects. Long-term safety data from the Phase 3 LIVERAGE and obesity programmes will provide a more comprehensive adverse events profile.

Cardiovascular & Metabolic Effects

Survodutide demonstrated changes in several cardiometabolic risk markers in Phase 2 data. Reductions in systolic and diastolic blood pressure were observed across dose groups, and lipid parameters including LDL cholesterol and triglycerides also moved in a favourable direction. These markers are hypothesis-generating until cardiovascular outcomes data are available.

These cardiometabolic observations matter because obesity frequently overlaps with cardiovascular disease, coronary artery disease, heart failure, and chronic kidney disease in trial populations. Boehringer Ingelheim has incorporated cardiovascular outcomes assessment into the Phase 3 programme, reflecting the regulatory expectation that obesity-drug candidates demonstrate cardiovascular safety and, where possible, event-level benefit.

SYNCHRONIZE CVOT: Survodutide’s Cardiovascular Outcomes Trial

Boehringer Ingelheim International GmbH has initiated the SYNCHRONIZE CVOT (cardiovascular outcomes trial) to evaluate cardiovascular outcomes in adults with established cardiovascular disease and obesity. The SYNCHRONIZE CVOT is one of the largest cardiovascular outcomes trials in the obesity drug development landscape, reflecting the growing regulatory expectation that weight-loss drug candidates demonstrate cardiovascular safety and potential cardiovascular benefit. The trial enrolled participants with increased CV risk, including prior myocardial infarction, prevalent heart failure, and atrial fibrillation.

SYNCHRONIZE CVOT Enrollment Criteria

The SYNCHRONIZE CVOT enrolled adults with overweight or obesity and established atherosclerotic cardiovascular disease or multiple cardiovascular risk factors. Key inclusion criteria included prior myocardial infarction, history of stroke or peripheral arterial disease, prevalent heart failure (NYHA class II–III), and atrial fibrillation. Participants across CKD risk categories were also eligible, provided they met the cardiovascular entry criteria. Boehringer Ingelheim Pharma GmbH coordinates clinical operations for the SYNCHRONIZE CVOT across multiple global sites.

Heart Failure Endpoints in SYNCHRONIZE CVOT

Heart failure is a pre-specified endpoint category within the SYNCHRONIZE CVOT programme. The trial assesses heart failure hospitalization, heart failure exacerbation, and composite cardiovascular outcomes including cardiovascular death and heart failure events. The Kansas City Cardiomyopathy Questionnaire is used within the trial to assess participant-reported heart failure outcomes, including symptom burden and functional status. Heart failure with preserved ejection fraction (HFpEF) is of particular research interest because it commonly overlaps with obesity and metabolic disease.

Cardiovascular Risk and Increased CV Risk Subgroups

Pre-specified subgroup analyses in the SYNCHRONIZE CVOT will examine outcomes in participants with increased CV risk, including prevalent heart failure, atrial fibrillation, and chronic kidney disease across CKD risk categories. Kansas City Cardiomyopathy Questionnaire scores at baseline and at pre-specified timepoints will be used to assess heart failure trajectory. The SYNCHRONIZE CVOT is expected to report primary results in 2028–2029, providing cardiovascular outcomes data that could differentiate survodutide from competitors.

Why Is Survodutide Being Developed for MASH?

MASH (metabolic dysfunction-associated steatohepatitis) is one of the most important adjacent metabolic conditions in incretin research. Many adults enrolled in obesity trials also have progressive fatty liver disease, non-cirrhotic MASH, or advanced fibrosis risk. A compound that can compete in both obesity and MASH attracts more strategic attention than one confined to a single indication. For a comparison of the leading injectable candidates, see our retatrutide vs tirzepatide vs CagriSema analysis.

The FDA has granted Breakthrough Therapy designation for survodutide in MASH, and the Phase 3 LIVERAGE (F2–F3 fibrosis) and LIVERAGE-Cirrhosis (compensated MASH cirrhosis) trials continue to recruit.

SYNCHRONIZE-MASLD has now reported Phase 3 data. The June 2026 Nature Medicine paper enrolled 216 adults with obesity and at-risk MASLD/MASH and compared once-weekly survodutide 6.0 mg with placebo for 48 weeks. Using the efficacy estimand, 84.2% of the survodutide group achieved at least a 30% MRI-PDFF liver-fat reduction versus 24.3% with placebo, and mean body weight changed −12.2% versus −1.0%. These are non-invasive imaging and weight endpoints; the LIVERAGE / LIVERAGE-Cirrhosis histology-outcome trials still matter for the broader MASH evidence package. Boehringer’s earlier 2024 MASH readout reported up to 83.0% histological MASH improvement versus 18.2% on placebo, up to 52.3% fibrosis improvement across F1–F3, and a 64.5% F2–F3 subanalysis endpoint for fibrosis improvement without worsening MASH. Those are trial endpoints, not clinical-use claims.

For context on the liver-disease landscape that survodutide is entering, a pre-specified substudy of the SELECT cardiovascular outcomes trial (Nature Medicine, April 2026) analysed semaglutide's effect in participants with elevated liver-fibrosis markers (FIB-4 ≥1.3). In that higher-fibrosis subgroup, semaglutide reduced the fatty liver index approximately 28% more than placebo (HR 0.72; P<0.0001) over 104 weeks. That data point establishes a GLP-1-class comparator benchmark; survodutide's glucagon arm is hypothesised to add hepatic lipid-oxidation activity beyond what GLP-1 alone provides, which is the mechanistic argument LIVERAGE will need to substantiate at Phase 3 scale.

Obesity Management & Long-Term Considerations

One critical research question in obesity pharmacology is durability after discontinuation. While survodutide’s Phase 2 data demonstrated substantial body weight reduction during active treatment, the durability of those effects after treatment cessation remains an open question. Weight regain has been observed after withdrawal of other GLP-1-based obesity medications, which makes long-term follow-up data important for the field.

Survodutide’s dual glucagon receptor agonism may offer theoretical advantages through enhanced energy expenditure, a metabolic pathway not meaningfully engaged by pure GLP-1 agonists. Whether this translates into durable outcomes or improved cardiometabolic endpoints in subgroups with chronic kidney disease, obstructive sleep apnoea, or cardiovascular risk will be clarified by the ongoing Phase 3 programme.

Key Research Publications and Evidence Base

Survodutide’s clinical data have been published in leading medical journals. Phase 2 obesity results appeared in Diabetes Obes Metab (Diabetes, Obesity and Metabolism), establishing the dose-response relationship and tolerability profile. MASH histology data were published in the N Engl J Med (New England Journal of Medicine), and the broader incretin literature in N Engl J Med and Lancet Diabetes Endocrinol provides context for the dual-agonist field.

Journal Publications and Disclosures

Research published in N Engl J Med, Lancet Diabetes Endocrinol, and Diabetes Obes Metab has shaped the clinical understanding of dual agonist approaches in obesity and liver-disease research. Several publications disclose sponsor support or author relationships with pharmaceutical companies, so this article prioritizes primary trial publications, ClinicalTrials.gov entries, and sponsor filings when describing endpoints.

Parallel Group Design and Trial Methodology

The Phase 2 survodutide trial used a parallel group, randomised, double-blind, placebo-controlled design. Each parallel group received a fixed dose of subcutaneous survodutide or matching placebo. Baseline characteristics—including body weight, body mass index, waist circumference, and cardiometabolic parameters—were balanced across parallel group assignments. All treated participants provided informed consent and were followed through the complete treatment period. Results were published with full access to supplementary data in Diabetes Obes Metab, with search terms and methodology documented per CONSORT guidelines. N Engl J Med and Lancet Diabetes Endocrinol have also published related research support for the dual agonist treatment of obesity.

Competitive Landscape: Additional Targets in Obesity

Survodutide competes in a rapidly expanding obesity drug pipeline with compounds targeting additional targets beyond the GLP-1 receptor. Structure Therapeutics is developing oral small-molecule GLP-1 receptor agonists that could offer broad spectrum access to the treatment of obesity without injectable administration. GI Dynamics has pursued device-based approaches to weight management, while integrated healthcare providers such as Optum Health are expanding obesity management programmes that incorporate both pharmacotherapy and behavioral interventions.

Regional Development and Global Trials

Boehringer Ingelheim International GmbH coordinates survodutide’s global clinical trial programme from its headquarters, with Boehringer Ingelheim Pharma GmbH managing manufacturing and drug supply. Clinical trial sites span multiple regions including North America, with investigators at academic medical centres in New Hampshire, Ontario Canada, and other locations contributing to enrollment. Bausch Health Canada and other pharmaceutical companies based in Ontario Canada have also invested in adjacent metabolic disease areas. The N Engl J Med and Lancet Diabetes Endocrinol continue to serve as primary publication venues for obesity trials conducted across these international networks, with compared with placebo results reported for all active treatment arms.

Both compounds engage glucagon-receptor signaling, but retatrutide adds GIP-receptor agonism as a third pathway. On Phase 3 data, retatrutide’s TRIUMPH-1 (28.3% at 80 wk) leads survodutide’s SYNCHRONIZE-1 (16.6% at 76 wk) on absolute weight loss. Survodutide’s differentiation today is the MASH evidence track — now including SYNCHRONIZE-MASLD plus the FDA-designated LIVERAGE / LIVERAGE-Cirrhosis programme — and the glucagon arm’s potential liver and cardiometabolic angle. For a mechanistic deep dive into how these receptors interact, see our explainer on the triple-agonist GIP, GLP-1, and glucagon pathway.